---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065031"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:44:58.088491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine Q1 net loss $34.1M, cash $694.7M; bitopertin NDA on track H2 2025

## Summary
- Ended Q1 with $694.7M cash; expects to fund operations into 2028 after $259M January offering.
- Net loss $34.1M vs $26.9M YoY; R&D expense $27.8M, SG&A $12.2M, both up on pipeline progress.
- Bitopertin NDA in erythropoietic protoporphyria (EPP) planned for H2 2025; APOLLO confirmatory trial initiated.
- DISC-3405 Phase 2 in polycythemia vera expected to start H1 2025; initial DISC-0974 data due H2 2025.
- Successful CMC-focused end-of-Phase-2 meeting with FDA; drug substance and product manufactured in US.

## SEC filing metadata
- accession: 0000950170-25-065031
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/0000950170-25-065031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000095017025065031/iron-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065031
- JSON: https://secwatch.observer/filing/0000950170-25-065031.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.